8-K
Axogen, Inc. (AXGN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2026
AXOGEN, INC.
(Exact Name of Registrant as Specified in Charter)
Minnesota
(State or Other Jurisdiction of
Incorporation or Organization)
001-36046
(Commission File Number)
41-1301878
(I.R.S. Employer Identification No.)
13631 Progress Boulevard, Suite 400 Alachua, Florida
(Address of principal executive offices)
32615
(Zip Code)
(386) 462-6800
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | AXGN | The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 24, 2026, Axogen, Inc. (the “Company”) issued a press release announcing its fourth quarter 2025 financial results. A copy of the press release is furnished as Exhibit 99.1.
The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 7.01 Regulation FD Disclosure
On February 24, 2026, the Company posted a fourth quarter 2025 financial results presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the financial results presentation from time to time in conversation with analysts, investors, and others. A copy of the presentation is furnished as Exhibit 99.2.
The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Axogen Inc. Earnings Press Release, dated February 24, 2026 |
| 99.2 | Axogen Inc. Fourth Quarter Financial Results Presentation, dated February 24, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AXOGEN, INC. | ||
|---|---|---|
| Dated: February 24, 2026 | By: | /s/ Marc Began |
| Marc Began | ||
| Executive Vice President, General Counsel and Chief Compliance Officer |
Document
Exhibit 99.1
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
ALACHUA and TAMPA, FL – February 24, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025.
Fourth Quarter Financial Results
•Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarter 2025 revenue.
•Fourth quarter 2025 gross margin was 74.1%, down from 76.1% for the fourth quarter of 2024, and down from 76.6% in the third quarter of 2025.
•Gross margin reflects one-time costs of approximately $1.9 million, or 3% for the fourth quarter of 2025, related to the U.S. Food and Drug Administration (“FDA”) Biologics License Application (“BLA”) approval of Avance®, of which 67% are non-cash and relate to the vesting of certain stock compensation awards containing FDA BLA approval of Avance® milestones.
•Net loss for the fourth quarter of 2025 was $13.2 million, or $0.28 per share, compared to a Net income of $0.5 million, or $0.01 per share for the fourth quarter of 2024.
•Adjusted net income for the fourth quarter of 2025 and 2024 were both $3.5 million, or $0.07 per share.
•Adjusted EBITDA was $6.5 million for the fourth quarter 2025, compared to $6.7 million for the fourth quarter of 2024.
•Cash and cash equivalents, restricted cash, and investments increased $5.7 million during the fourth quarter of 2025.
“2025 was a remarkable year of financial and operational achievement for Axogen, as we attained or progressed every objective expected of our strategic plan. With the FDA’s approval of our Biologics License Application for Avance® as the only implantable biologic indicated for treatment of peripheral nerve discontinuities, and the continued demonstration of the effectiveness and predictability of our market development strategies, we are confident we have a foundation for future growth and advancement of our mission to make restoration of peripheral function a standard of care,” commented Michael Dale, President and CEO of Axogen, Inc. “Importantly for shareholders, we exited 2025 financially stronger and positioned to continue our important work profitably while generating positive cash flow.”
Full-Year Financial Results
•Full-year 2025 revenue was $225.2 million, a 20.2% increase compared to 2024 revenue of $187.3 million.
•Gross margin was 74.3% for the full-year 2025, compared to 75.8% in 2024.
•Gross margin reflects one-time costs of approximately $1.9 million, or 1% for the full-year 2025, related to the FDA BLA approval of Avance®, of which 67% are non-cash and relate to the vesting of certain stock compensation awards containing FDA BLA approval of Avance® milestones.
•Net loss for the full-year 2025 was $15.7 million, or $0.34 per share, compared to $10.0 million, or $0.23 per share for 2024.
•Adjusted net income was $14.4 million for the full-year 2025, or $0.29 per share, compared to $5.9 million for the full-year, or $0.13 per share for 2024.
•Adjusted EBITDA was $27.9 million for the full-year 2025, compared to $19.8 million for 2024.
•As of December 31, 2025, cash and cash equivalents, restricted cash, and investments was $45.5 million, as compared to $39.5 million as of December 31, 2024, an increase of $6.0 million.
Summary of Business Highlights
•Fourth quarter and full-year 2025 revenue growth was broad-based, including double-digit growth in all markets, which includes Extremities, Oral Maxillofacial & Head and Neck, and Breast.
•Expanded coverage and reimbursement for peripheral nerve repair using synthetic conduits and allografts, increasing the total number of newly covered lives in 2025 to approximately 19.8 million and raising commercial payer coverage to more than 65%.
•On December 3, 2025, the FDA approved the BLA for Avance® (acellular nerve allograft-arwx).
•Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code, increasing Avance facility reimbursement 40% year-over-year to $8,965 for hospital outpatient and 35% to $6,157 for ASC-based procedures.
•On January 23, 2026, Axogen closed an upsized public offering with the sale of 4.6 million shares of common stock, yielding net proceeds of $133.3 million. From these net proceeds, $69.7 million were used to fully repay and terminate our Oberland loan facility on January 28, 2026. Remaining funds will be available for working capital, capital expenditures, and other general corporate purposes.
2026 Financial Guidance
We expect 2026 revenue growth to be at least 18%, or $265.7 million, for the full-year and gross margin to be in the range of 74% to 76%. Additionally, we expect to be free cash flow positive for the full-year.
Conference Call
The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link.
Following the conference call, a replay will be available in the Investors section of the Company’s website at www.axogeninc.com under Investors.
About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical
damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
For more information, visit www.axogeninc.com.
Cautionary Statements Concerning Forward-Looking Statements
This press release and accompanying earnings call contain “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, all statements under the heading “2026 Financial Guidance” and statements regarding our business model optimization plans; market development strategies and objectives; our expectations around the potential positive impact on our business of expanded coverage and reimbursement for peripheral nerve injuries using synthetic conduits or allografts; our ability to sustain growth, operate profitably and generate positive cash flows and fund our market development initiatives; the anticipated use of proceeds from our recent public offering; and our business purpose to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “priorities,” “objectives,” “targets,” “intends,” “plan(s),” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, potential disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon and product adoption rates, market awareness of our products, the projected TAM for targeted markets, as well as those risk factors described under Part I, Item 1A., “Risk Factors,” in our most recent Annual Report on Form 10-K and other risks and uncertainties that may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.
About Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further exclude noncash stock compensation expense, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income and Adjusted Net Income Per Common Share - diluted which excludes noncash stock compensation expense from Net (Loss) Income and Net (Loss) Income Per Common Share - diluted. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.
We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-
making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.
| Contact:<br><br>Axogen, Inc.<br><br>InvestorRelations@axogeninc.com |
|---|
Axogen, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
| December 31,<br>2025 | December 31,<br>2024 | |||
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 35,548 | $ | 27,554 |
| Restricted cash | 4,000 | 6,000 | ||
| Investments | 5,980 | 5,928 | ||
| Accounts receivable, net of allowance for doubtful accounts of $948 and $788, respectively | 26,169 | 24,105 | ||
| Inventory | 42,373 | 33,183 | ||
| Prepaid expenses and other assets | 6,352 | 2,447 | ||
| Total current assets | 120,422 | 99,217 | ||
| Property and equipment, net | 81,783 | 84,667 | ||
| Operating lease right-of-use assets | 12,732 | 14,265 | ||
| Intangible assets, net | 6,750 | 5,579 | ||
| Total assets | $ | 221,687 | $ | 203,728 |
| Liabilities and shareholders’ equity | ||||
| Current liabilities: | ||||
| Accounts payable and accrued expenses | $ | 21,184 | $ | 28,641 |
| Current maturities of long-term lease obligations | 2,372 | 1,969 | ||
| Total current liabilities | 23,556 | 30,610 | ||
| Long-term debt, net of debt discount and financing fees | 48,387 | 47,496 | ||
| Long-term lease obligations | 16,870 | 19,221 | ||
| Debt derivative liabilities | 3,886 | 2,400 | ||
| Other long-term liabilities | 141 | 94 | ||
| Total liabilities | 92,840 | 99,821 | ||
| Shareholders’ equity: | ||||
| Common stock, $0.01 par value per share; 100,000,000 shares authorized; 47,199,797 and 44,148,836 shares issued and outstanding, respectively | 472 | 441 | ||
| Additional paid-in capital | 435,338 | 394,726 | ||
| Accumulated deficit | (306,963) | (291,260) | ||
| Total shareholders’ equity | 128,847 | 103,907 | ||
| Total liabilities and shareholders’ equity | $ | 221,687 | $ | 203,728 |
Axogen, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Years Ended | |||||||
|---|---|---|---|---|---|---|---|---|
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | |||||
| Revenues | $ | 59,904 | $ | 49,405 | $ | 225,208 | $ | 187,338 |
| Cost of goods sold | 15,495 | 11,830 | 57,855 | 45,361 | ||||
| Gross profit | 44,409 | 37,575 | 167,353 | 141,977 | ||||
| Costs and expenses: | ||||||||
| Sales and marketing | 27,211 | 20,051 | 97,740 | 78,461 | ||||
| Research and development | 12,376 | 6,731 | 32,885 | 27,767 | ||||
| General and administrative | 14,594 | 8,866 | 44,577 | 39,036 | ||||
| Total costs and expenses | 54,181 | 35,648 | 175,202 | 145,264 | ||||
| (Loss) income from operations | (9,772) | 1,927 | (7,849) | (3,287) | ||||
| Other income (expense): | ||||||||
| Investment income | 352 | 325 | 1,168 | 1,141 | ||||
| Interest expense | (1,718) | (1,801) | (7,702) | (8,206) | ||||
| Change in fair value of debt derivative liabilities | (2,018) | 45 | (1,487) | 587 | ||||
| Other (expense) income, net | — | (46) | 167 | (199) | ||||
| Total other expense, net | (3,384) | (1,477) | (7,854) | (6,677) | ||||
| Net (loss) income | $ | (13,156) | $ | 450 | $ | (15,703) | $ | (9,964) |
| Weighted average common shares outstanding — basic | 46,929,309 | 44,876,659 | 46,050,266 | 44,257,754 | ||||
| Weighted average common shares outstanding — diluted | 46,929,309 | 48,064,916 | 46,050,266 | 44,257,754 | ||||
| Net (loss) income per common share — basic | $ | (0.28) | $ | 0.01 | $ | (0.34) | $ | (0.23) |
| Net (loss) income per common share — diluted | $ | (0.28) | $ | 0.01 | $ | (0.34) | $ | (0.23) |
Axogen, Inc.
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Years Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | |||||||||
| Net (loss) income | $ | (13,156) | $ | 450 | $ | (15,703) | $ | (9,964) | ||||
| Depreciation and amortization expense | 1,727 | 1,700 | 6,975 | 6,734 | ||||||||
| Investment income | (352) | (325) | (1,168) | (1,141) | ||||||||
| Income tax expense | — | 21 | 4 | 97 | ||||||||
| Interest expense | 1,718 | 1,801 | 7,702 | 8,206 | ||||||||
| EBITDA - non-GAAP | $ | (10,063) | $ | 3,647 | $ | (2,190) | $ | 3,932 | ||||
| EBITDA margin - non-GAAP | (16.8) | % | 7.4 | % | (1.0) | % | 2.1 | % | ||||
| Noncash stock-based compensation expense | 16,611 | 3,076 | 30,112 | 15,906 | ||||||||
| Adjusted EBITDA - non-GAAP | $ | 6,548 | $ | 6,723 | $ | 27,922 | $ | 19,838 | ||||
| Adjusted EBITDA margin - non-GAAP | 10.9 | % | 13.6 | % | 12.4 | % | 10.6 | % | ||||
| Net (loss) income | $ | (13,156) | $ | 450 | $ | (15,703) | $ | (9,964) | ||||
| Noncash stock-based compensation expense | 16,611 | 3,076 | 30,112 | 15,906 | ||||||||
| Adjusted net income - non-GAAP | $ | 3,455 | $ | 3,526 | $ | 14,409 | $ | 5,942 | ||||
| Weighted average common shares outstanding - diluted GAAP | 46,929,309 | 48,064,916 | 46,050,266 | 44,257,754 | ||||||||
| Weighted average common shares outstanding - diluted non-GAAP (1) | 52,230,508 | 48,064,916 | 49,812,186 | 46,197,934 | ||||||||
| Net (loss) income per common share - diluted - GAAP | $ | (0.28) | $ | 0.01 | $ | (0.34) | $ | (0.23) | ||||
| Noncash stock-based compensation expense | 0.35 | 0.06 | 0.65 | 0.36 | ||||||||
| Adjusted net income per common share - diluted - non-GAAP (1) | $ | 0.07 | $ | 0.07 | $ | 0.29 | $ | 0.13 |
__________
(1)Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding for the three months ended December 31, 2025 and the years ended December 31, 2025 and 2024. However, considering the adjusted net income position for the three months ended December 31, 2025 and the years ended December 31, 2025 and 2024, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.
Axogen, Inc.
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(unaudited)
(in thousands, except share amounts)
| Common Stock | Additional Paid-in<br>Capital | Accumulated<br>Deficit | Total Shareholders'<br>Equity | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | ||||||||
| Three Months Ended December 31, 2025 | |||||||||
| Balance at September 30, 2025 | 46,117,283 | $ | 461 | $ | 414,151 | $ | (293,807) | $ | 120,805 |
| Net loss | — | — | — | (13,156) | (13,156) | ||||
| Stock-based compensation | — | — | 16,611 | — | 16,611 | ||||
| Issuance of restricted and performance stock units | 606,645 | 6 | (6) | — | — | ||||
| Exercise of stock options and employee stock purchases under the ESPP | 475,869 | 5 | 4,582 | — | 4,587 | ||||
| Balance at December 31, 2025 | 47,199,797 | $ | 472 | $ | 435,338 | $ | (306,963) | $ | 128,847 |
| Year Ended December 31, 2025 | |||||||||
| Balance at December 31, 2024 | 44,148,836 | $ | 441 | $ | 394,726 | $ | (291,260) | $ | 103,907 |
| Net loss | — | — | — | (15,703) | (15,703) | ||||
| Stock-based compensation | — | — | 30,112 | — | 30,112 | ||||
| Issuance of restricted and performance stock units | 1,907,707 | 19 | (19) | — | — | ||||
| Exercise of stock options and employee stock purchases under the ESPP | 1,143,254 | 12 | 10,519 | — | 10,531 | ||||
| Balance at December 31, 2025 | 47,199,797 | $ | 472 | $ | 435,338 | $ | (306,963) | $ | 128,847 |
| Three Months Ended December 31, 2024 | |||||||||
| Balance at September 30, 2024 | 44,002,323 | $ | 440 | $ | 390,677 | $ | (291,710) | $ | 99,407 |
| Net income | — | — | — | 450 | 450 | ||||
| Stock-based compensation | — | — | 3,076 | — | 3,076 | ||||
| Issuance of restricted and performance stock units | 17,170 | — | — | — | — | ||||
| Exercise of stock options and employee stock purchases under the ESPP | 129,343 | 1 | 973 | — | 974 | ||||
| Balance at December 31, 2024 | 44,148,836 | $ | 441 | $ | 394,726 | $ | (291,260) | $ | 103,907 |
| Year Ended December 31, 2024 | |||||||||
| December 31, 2023 | 43,124,496 | $ | 431 | $ | 376,530 | $ | (281,296) | $ | 95,665 |
| Net loss | — | — | — | (9,964) | (9,964) | ||||
| Stock-based compensation | — | — | 15,906 | — | 15,906 | ||||
| Issuance of restricted and performance stock units | 712,741 | 7 | (7) | — | — | ||||
| Exercise of stock options and employee stock purchases under the ESPP | 311,599 | 3 | 2,297 | — | 2,300 | ||||
| Balance at December 31, 2024 | 44,148,836 | $ | 441 | $ | 394,726 | $ | (291,260) | $ | 103,907 |
Axogen, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
| Years Ended | ||||
|---|---|---|---|---|
| December 31, 2025 | December 31, 2024 | |||
| Cash flows from operating activities: | ||||
| Net loss | $ | (15,703) | $ | (9,964) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||
| Depreciation | 6,660 | 6,467 | ||
| Amortization of right-of-use assets | 1,533 | 1,103 | ||
| Amortization of intangible assets | 315 | 267 | ||
| Amortization of debt discount and deferred financing fees | 891 | 893 | ||
| Provision for bad debts | 400 | 650 | ||
| Change in fair value of debt derivative liabilities | 1,487 | (587) | ||
| Investment gains, net | (329) | (155) | ||
| Impairment of long-lived assets | 64 | — | ||
| Stock-based compensation expense | 30,112 | 15,906 | ||
| Change in operating assets and liabilities: | ||||
| Accounts receivable | (2,464) | 392 | ||
| Inventory | (9,190) | (10,163) | ||
| Prepaid expenses and other assets | (3,905) | 784 | ||
| Accounts payable and accrued expenses | (7,158) | 125 | ||
| Operating lease obligations | (1,937) | (1,603) | ||
| Cash paid for interest portion of financing lease obligations | (11) | (4) | ||
| Other long-term liabilities | 47 | 424 | ||
| Net cash provided by operating activities | 812 | 4,535 | ||
| Cash flows from investing activities: | ||||
| Purchase of property and equipment | (3,745) | (3,101) | ||
| Purchase of investments | (13,723) | (5,773) | ||
| Proceeds from sale of investments | 14,000 | — | ||
| Cash payments for intangible assets | (1,849) | (1,423) | ||
| Net cash used in investing activities | (5,317) | (10,297) | ||
| Cash flows from financing activities: | ||||
| Cash paid for debt portion of financing lease obligations | (32) | (10) | ||
| Proceeds from exercise of stock options and ESPP stock purchases | 10,531 | 2,300 | ||
| Net cash provided by financing activities | 10,499 | 2,290 | ||
| Net increase (decrease) in cash and cash equivalents, and restricted cash | 5,994 | (3,472) | ||
| Cash and cash equivalents, and restricted cash, beginning of period | 33,554 | 37,026 | ||
| Cash and cash equivalents, and restricted cash, end of period | $ | 39,548 | $ | 33,554 |
axgnq42025earningsreleas
Q4 and 2025 Financial Results February 24, 2026 1
Disclaimer 2 Forward-looking Statements This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are statements that are not historical facts and relate to future conditions, events, or results. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “objectives,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements related to: clinical development activities, including expansion into prostate applications; commercial growth initiatives, including planned expansion of breast and extremities sales specialists; market development opportunities; expectations regarding disciplined, profitable growth and margin improvement; financial guidance and outlook for 2026, including projected revenue growth, net cash flow, gross margins, and other operating performance metrics; and statements regarding our training and education initiatives, reimbursement and market access efforts, and research and development activities. Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, risks related to global supply chain conditions, inflationary pressures, hospital staffing challenges, product development and product potential, clinical enrollment timing and outcomes, regulatory processes and approvals, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, geopolitical and macroeconomic conditions, including armed conflicts and government actions or policies that may affect our business, tax position, or regulatory processes, as well as those risk factors described under Part I, Item 1A., “Risk Factors,” of our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements. About Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, Adjusted EBITDA, which further excludes non-cash stock compensation expense, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income and Adjusted Net Income Per Common Share - diluted which excludes noncash stock compensation expense from Net (Loss) Income and Net (Loss) Income Per Common Share - diluted, respectively. We also use the Operational Cashflow metric, which corresponds to Net change in cash, cash equivalents, restricted cash, and investments, less cashflow from issuance or repayment of long-term debt. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements.
3 Michael Dale President and Chief Executive Officer Q4 & 2025 Business Highlights and 2026 Goals
Agenda 4 Q4 and 2025 Financials and 2026 Guidance Lindsey Hartley, Chief Financial Officer Q&A Michael Dale, Lindsey Hartley, Jens Kemp, Chief Marketing Officer Rick Ditto, VP Global Health Economic, Reimbursement & Policy Q4 and 2025 Business Highlights and 2026 Goals Michael Dale, President and Chief Executive Officer
Strategic Priorities 01 GROWTH 15–20% Revenue CAGR + Operating Leverage 02 MARKET DEVELOPMENT Elective & Planned Procedures + Prostate market development 03 COMMERCIAL EXPANSION Infrastructure and Sales Force expansion 04 COMMERCIAL EXCELLENCE Continuous business model and customer creation process optimization by market 05 STANDARD OF CARE Clinical evidence generation for societal support, standard of care & coverage requirements 06 INNOVATION Product development to drive better benefit versus risk profiles in nerve care 5
6 Strategic Priorities 2025 Business Highlights 0 1 G R OW TH 15–20% Revenue CAGR + Operating Leverage Q4 Revenue $59.9M, +21.3% YoY Full-Year Revenue $225.2M, +20.2% YoY Capital Structure Raised $133.3M; retired $69.7M term loan 2026 Target Disciplined profitable growth; improving margins 0 2 M A R K E T D E V E L O PM EN T Elective & Planned + Prostate Extremities Solid traumatic & chronic growth; most mature market OMF / H&N High double-digit growth; quality-of-life recognition growing Breast Fast-growing; accelerating Resensation adoption Prostate 100+ procedures; 10 sites; surgical technique standardized 2026 Prostate Meaningful clinical signals expected in 2H 2026 0 3 C OMME R C I A L E X P A N S I O N Infrastructure + Sales Force Growth Breast 21 reps, 2 regional directors Extremities 117 reps, 15 regional directors OMF / H&N 3 field-based market development managers Prostate Added 3 clinical development managers and 1 director 2026 Breast / Ext. Grow to ~30 breast reps; ~130 extremity reps 6
7 Strategic Priorities 2025 Business Highlights 2026 2026 2026 0 4 C OMME R C I A L E X C E L L E N C E HiPo Accounts, Productivity & Education HiPo Revenue 61% of growth from HiPo accounts Productivity +21% avg. HiPo account productivity Active Accounts 679 HiPo accounts; +131 active surgeons Education Exceeded surgeon training targets across all markets HiPo & Training 60% growth from HiPo; +18% productivity; 100+ new surgeons 0 5 S T A N D A R D O F C A R E Evidence, Coverage & Avance® FDA BLA Exclusivity 12 years of U.S. market exclusivity Avance® BLA Approved First & only FDA-approved biologic for peripheral nerve repair Societies AAHS & ASRM recognize allograft as standard of care (1) Coverage +19.8M lives added; commercial coverage now above 65% Payer & Coverage Pursue near-universal US coverage (est. 2H 2028) 0 6 I N NO V A T I O N R&D + Therapeutic Reconstruction Program Updates Detailed updates on individual R&D programs in 2H 2026 Ease of Coaptation R&D focused on faster, more consistent nerve coaptation Chronic Injuries Advancing non-transected and chronic nerve repair solutions Therapeutic Reconstruction Next-gen technologies to improve nerve regeneration Clinical Studies BLA enables prioritized breast & mixed/motor nerve studies 7 (1) The American Association of Hand Surgery (“AAHS”) and the American Society for Reconstructive Microsurgery (“ASRM”) released official position statements recognizing nerve allograft as a standard medical practice option for the treatment of peripheral nerve defects during the third quarter of 2025.
8 Lindsey Hartley Chief Financial Officer Q4 & 2025 Financials and 2026 Guidance Discussion
Q4 & 2025 Financial Performance 9 Q4 & 2025 Revenue ($ in millions) $49.4 $187.3 $59.9 $225.2 2024 2025 Q4 Annual $— $40.0 $80.0 $120.0 $160.0 $200.0 $240.0 Q4 & 2025 Gross Margin % 76.1% 75.8% 74.1% 74.3% 2024 2025 Q4 Annual 73.0% 73.5% 74.0% 74.5% 75.0% 75.5% 76.0% 76.5% -2pp+21.3% (1) Q4 2025 and full-year 2025 include $1.9M of one-time costs, of which $1.3M is non-cash stock-based compensation, related to the U.S. Food and Drug Administration (“FDA”) Biologics License Application (“BLA”) approval of Avance®, impacting gross margin by -3.3% and -0.9%, respectively. (1) -1.5pp+20.2%
Q4 & 2025 Financial Performance Gaining operating leverage with topline growth ($ in millions) 10 Q4 2025 Q4 2024 2025 2024 Revenues $59.9 $49.4 $225.2 $187.3 Sales and marketing expenses $27.2 $20.1 $97.7 $78.5 Research and development expenses 12.4 6.7 32.9 27.8 General and administrative expenses 14.6 8.9 44.6 39.0 Total costs and expenses (1) $54.2 $35.6 $175.2 $145.3 YoY change % 52.0% 20.6% Change as a % of revenue (2) 18.3% 0.3% (1) Q4 2025 and full-year 2025 total costs and expenses include $7.2M of non-cash, one-time stock-based compensation costs related to the FDA BLA approval for Avance® ($0.7M in sales and marketing, $4.6M in research and development, and $1.9M in general and administrative expenses). (2) One-time stock-based compensation costs related to the FDA BLA approval for Avance® impacted Q4 2025 and full-year 2025 operating margin by approximately -12.1% and -3.2%, respectively.
Q4 & 2025 Financial Performance ($ in millions, except per share data) 11 * Excludes stock-based compensation. See non-GAAP reconciliations included in Appendix. Q4 2025 Q4 2024 2025 2024 Net (loss) income $(13.2) $0.5 $(15.7) $(10.0) Diluted EPS $(0.28) $0.01 $(0.34) $(0.23) Adjusted net income* $3.5 $3.5 $14.4 $5.9 Adjusted Diluted EPS* $0.07 $0.07 $0.29 $0.13 Adjusted EBITDA* $6.5 $6.7 $27.9 $19.8 Adjusted EBITDA margin* 10.9% 13.6% 12.4% 10.6%
Q4 and 2025 Financial Performance Operating cash flow ($ in millions) 12 * Cash, cash equivalents, restricted cash, and investments. December 31, 2025 Q4 Change 2025 Change Operational cash* $45.5 +$5.7 +$6.0
Guidance for the Full-Year 2026 Revenue growth of at least 18% or $265.7 million Gross margin of 74% to 76% Net free cash flow positive 13
Michael Dale President and Chief Executive Officer Jens Kemp Chief Marketing Officer Rick Ditto VP, Global Health Economics, Reimbursement & Policy 14 Lindsey Hartley Chief Financial Officer Q&A
Thank you
Appendix 16
17 Non-GAAP Reconciliations: Three Months Ended December 31, Years Ended December 31, (in thousands, except share and per share amounts) 2025 2024 2025 2024 Net (loss) income $ (13,156) $ 450 $ (15,703) $ (9,964) Depreciation and amortization expense 1,727 1,700 6,975 6,734 Investment income (352) (325) (1,168) (1,141) Income tax expense — 21 4 97 Interest expense 1,718 1,801 7,702 8,206 EBITDA - non-GAAP $ (10,063) $ 3,647 $ (2,190) $ 3,932 EBITDA margin - non-GAAP (16.8) % 7.4 % (1.0) % 2.1 % Noncash stock-based compensation expense 16,611 3,076 30,112 15,906 Adjusted EBITDA - non-GAAP $ 6,548 $ 6,723 $ 27,922 $ 19,838 Adjusted EBITDA margin - non-GAAP 10.9 % 13.6 % 12.4 % 10.6 % Net (loss) income $ (13,156) $ 450 $ (15,703) $ (9,964) Noncash stock-based compensation expense 16,611 3,076 30,112 15,906 Adjusted net income - non-GAAP $ 3,455 $ 3,526 $ 14,409 $ 5,942 Weighted average common shares outstanding - diluted GAAP 46,929,309 48,064,916 46,050,266 44,257,754 Weighted average common shares outstanding - diluted non-GAAP (1) 52,230,508 48,064,916 49,812,186 46,197,934 Net (loss) income per common share - diluted - GAAP $ (0.28) $ 0.01 $ (0.34) $ (0.23) Noncash stock-based compensation expense 0.35 0.06 0.65 0.36 Adjusted net income per common share - diluted - non- GAAP (1) $ 0.07 $ 0.07 $ 0.29 $ 0.13 ___________ (1) Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding for the three months ended December 31, 2025 and the years ended December 31, 2025 and 2024. However, considering the adjusted net income position for the three months ended December 31, 2025 and the years ended December 31, 2025 and 2024, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.
